Sp116
RADIOLOGIC VS. ENDOSCOPIC SURVEILLANCE OF PANCREATIC CYSTS
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
For years, presentations at DDW focused on endoscopic diagnosis of pancreatic cystic neoplasms. There has been a recent surge of published studies testing various interventions for treating cystic neoplasms (endoscopic ultrasound-guided). This session will put these studies in perspective and compare them with surgical resection on the one hand and surveillance on the other.
For years, presentations at DDW focused on endoscopic diagnosis of pancreatic cystic neoplasms. There has been a recent surge of published studies testing various interventions for treating cystic neoplasms (endoscopic ultrasound-guided). This session will put these studies in perspective and compare them with surgical resection on the one hand and surveillance on the other.
Presenter
Stanford University
Tracks
Related Products
MULTI-CENTER BLINDED VALIDATION OF THE DIAGNOSTIC UTILITY OF CYST GLUCOSE AND AMPHIREGULIN TO DIFFERENTIATE MUCINOUS FROM NON-MUCINOUS PANCREATIC CYSTS.
BACKGROUND AND AIMS: Currently, most patients with branch duct intraductal papillary mucinous neoplasms (BD-IPMN) are offered indefinite surveillance, resulting in health care costs with questionable benefits regarding cancer prevention…
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PANEL DISCUSSION
For years, presentations at DDW focused on endoscopic diagnosis of pancreatic cystic neoplasms. There has been a recent surge of published studies testing various interventions for treating cystic neoplasms (endoscopic ultrasound-guided)…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
